Canvuparatide

Phase 3

MMBX Biosciences

Canvuparatide is one of 7 therapeutic programs targeting Hypoparathyroidism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HypoparathyroidismRecruiting

HypoparathyroidismPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Rocaltrol

Calciferol

Canvuparatide

1 5

Calcium

Eli Lilly

Preclinical

1 6

EXT608

EExtend Biosciences Inc.

Phase 2

1 7

Yorvipath

Ascendis Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Hypoparathyroidism

NCT07699471

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism

Recruiting·MMBX Biosciences·Phase 3·NCT07699471·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Canvuparatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Canvuparatide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — MBX Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMBX Biosciences

Canvuparatide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News